Should I buy or sell Fate Therapeutics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. View FATE analyst ratings or view top-rated stocks .

What is Fate Therapeutics' stock price target for 2024?

12 analysts have issued 12 month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $6.73 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View analysts price targets for FATE or view top-rated stocks among Wall Street analysts .

How have FATE shares performed in 2024?

Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE stock has increased by 42.8% and is now trading at $5.34. View the best growth stocks for 2024 here .

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,490,000 shares, an increase of 25.3% from the March 15th total of 13,160,000 shares. Based on an average daily trading volume, of 2,860,000 shares, the short-interest ratio is presently 5.8 days. Approximately 19.0% of the shares of the stock are sold short. View Fate Therapeutics' Short Interest .

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our FATE earnings forecast .

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative trailing twelve-month return on equity of 38.17%. During the same quarter last year, the company posted ($0.58) earnings per share.

What ETFs hold Fate Therapeutics' stock?

ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH) . iShares Genomics Immunology and Healthcare ETF (IDNA) .

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com . Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA) , CRISPR Therapeutics (CRSP) , Juno Therapeutics (JUNO) , NVIDIA (NVDA) , Sangamo Therapeutics (SGMO) , Advanced Micro Devices (AMD) , Exelixis (EXEL) , Neurocrine Biosciences (NBIX) , Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD) .

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FATE

Fate Therapeutics (FATE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free FATE Stock Alerts

$5.05

-0.22 (-4.17%)

(As of 02:51 PM ET)

Compare

Today's Range: $5.04
▼
$5.35
50-Day Range: $5.27
▼
$8.35
52-Week Range: $1.63
▼
$8.83

Volume: 936,968 shs
Average Volume: 2.76 million shs
Market Capitalization: $501.16 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.73

Get Fate Therapeutics alerts:

Fate Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.08 Rating Score
Upside/Downside: 26.0% Upside
$6.73 Price Target
Short Interest: Bearish
19.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.70
Upright™ Environmental Score
News Sentiment: 0.69
Based on 5 Articles This Week
Insider Trading: Selling Shares
$9,245 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.94) to ($1.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

164th out of 914 stocks

Biological Products, Except Diagnostic Industry

19th out of 153 stocks

4.0

Analyst's Opinion

Consensus Rating
Fate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 2 buy ratings, 9 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Fate Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
19.01% of the float of Fate Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Fate Therapeutics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Fate Therapeutics has recently increased by 25.30%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fate Therapeutics does not currently pay a dividend.
Dividend Growth
Fate Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Fate Therapeutics has received a 75.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Fate Therapeutics is -0.70.

2.6

News and Social Media Coverage

News Sentiment
Fate Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Fate Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for FATE on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,245.00 in company stock.
Percentage Held by Insiders
Only 5.04% of the stock of Fate Therapeutics is held by insiders.
Percentage Held by Institutions
97.54% of the stock of Fate Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fate Therapeutics are expected to grow in the coming year, from ($1.94) to ($1.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fate Therapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fate Therapeutics is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fate Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

This Little-Known Stock Controls the Future of AI

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Fate Therapeutics Stock (NASDAQ:FATE)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FATE Stock News Headlines

April 13, 2024 | americanbankingnews.com

Fate Therapeutics (NASDAQ:FATE) Stock Rating Reaffirmed by Needham & Company LLC

April 12, 2024 | americanbankingnews.com

Fate Therapeutics (NASDAQ:FATE) Shares Gap Down to $6.76

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

April 10, 2024 | msn.com

A promising target for new RNA therapeutics now accessible

April 3, 2024 | yahoo.com

Terminator: Edward Furlong Addresses John Connor’s Death In Dark Fate

April 3, 2024 | uk.movies.yahoo.com

‘It Was A Mixed Feeling’: Terminator’s Edward Furlong Opens Up About Shooting His Controversial John Connor Cameo In Dark Fate

April 3, 2024 | finance.yahoo.com

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

April 2, 2024 | globenewswire.com

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

April 18, 2024 | Weiss Ratings (Ad)

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

March 31, 2024 | nz.news.yahoo.com

X Factor star Lucy Spraggan says Simon Cowell will walk her down the aisle at wedding

March 31, 2024 | msn.com

I visited Mother Mercy to learn more about their new Twist of Fate experience - and tried it out for myself

March 29, 2024 | markets.businessinsider.com

Cautious Outlook on Fate Therapeutics: Sell Rating Maintained Amid Competitive and Validation Concerns

March 24, 2024 | benzinga.com

Fate Therapeutics Stock (NASDAQ:FATE), Quotes and News Summary

March 19, 2024 | markets.businessinsider.com

Evaluating Fate Therapeutics: Insights From 5 Financial Analysts

March 19, 2024 | markets.businessinsider.com

Fate Therapeutics Prices $100 Mln Of Public Offering, Concurrent Private Placement

March 19, 2024 | msn.com

Fate Therapeutics announces pricing of $100M underwritten offering and concurrent private placement

March 19, 2024 | globenewswire.com

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

March 16, 2024 | finance.yahoo.com

FATE Apr 2024 5.000 put

March 16, 2024 | finance.yahoo.com

FATE Aug 2024 5.000 put

March 16, 2024 | finance.yahoo.com

FATE Apr 2024 7.500 put

March 14, 2024 | msn.com

Vindictus: Defying Fate is worth trying for free even if you never played the MMO

March 7, 2024 | finance.yahoo.com

FATE Mar 2024 10.000 put

March 6, 2024 | finanznachrichten.de

Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 5, 2024 | globenewswire.com

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | finance.yahoo.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript

March 1, 2024 | globenewswire.com

Fate Therapeutics to Present at Upcoming March Investor Conferences

March 1, 2024 | markets.businessinsider.com

Fate Therapeutics: Buy Rating Affirmed Amid Promising Pipeline and Upcoming Oncology Catalysts

See More Headlines

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:FATE
CUSIP: N/A
CIK: 1434316
Web: www.fatetherapeutics.com
Phone: (858) 875-1800
Fax: N/A
Employees: 181
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.73
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +27.7%
Consensus Rating: Hold
Rating Score (0-4): 2.08
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-160,930,000.00
Net Margins: -253.30%
Pretax Margin: -253.30%
Return on Equity: -38.17%
Return on Assets: -28.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.48
Quick Ratio: 8.48

Sales & Book Value

Annual Sales: $63.53 million
Price / Sales: 8.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.74 per share
Price / Book: 1.41

Miscellaneous

Outstanding Shares: 99,240,000
Free Float: 94,236,000
Market Cap: $522.99 million
Optionable: Optionable
Beta: 1.66

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. J. Scott Wolchko (Age 54)
Founder, CEO, President & Director
Comp: $645k
Mr. Edward J. Dulac III (Age 48)
Chief Financial Officer
Comp: $455k
Ms. Cindy R. Tahl J.D. (Age 51)
General Counsel, Corporate Secretary & Compliance Officer
Comp: $455k
Dr. Bahram Valamehr Ph.D. (Age 47)
Chief Research & Development Officer
Comp: $455k
Mr. Jim Beitel M.B.A.
Senior Vice President of Corporate Development
Dr. Jerome Bressi Ph.D.
Senior Vice President of Regulatory & Quality
Dr. Barbara Hickingbottom
Senior VP of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FATE Stock Analysis - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.
What is Fate Therapeutics' stock price target for 2024?: 12 analysts have issued 12 month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $6.73 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.
How have FATE shares performed in 2024?: Fate Therapeutics' stock was trading at $3.74 on January 1st, 2024. Since then, FATE stock has increased by 42.8% and is now trading at $5.34.
View the best growth stocks for 2024 here.
Are investors shorting Fate Therapeutics?: Fate Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 16,490,000 shares, an increase of 25.3% from the March 15th total of 13,160,000 shares. Based on an average daily trading volume, of 2,860,000 shares, the short-interest ratio is presently 5.8 days. Approximately 19.0% of the shares of the stock are sold short.
View Fate Therapeutics' Short Interest.
When is Fate Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our FATE earnings forecast.
How were Fate Therapeutics' earnings last quarter?: Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Monday, February, 26th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.12. The biopharmaceutical company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative trailing twelve-month return on equity of 38.17%. During the same quarter last year, the company posted ($0.58) earnings per share.

What ETFs hold Fate Therapeutics' stock?: ETFs with the largest weight of Fate Therapeutics (NASDAQ:FATE) stock in their portfolio include WisdomTree BioRevolution Fund (WDNA) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).iShares Genomics Immunology and Healthcare ETF (IDNA).
What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?: 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Fate Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).
How do I buy shares of Fate Therapeutics?: Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FATE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fate Therapeutics (FATE) Stock Price, News & Analysis

Fate Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Fate Therapeutics Stock (NASDAQ:FATE)

FATE Stock Price History

FATE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FATE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™